SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) December 3, 1997
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On December 3, 1997, Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that a new $2.146 million contract has
been received from NeuroControl Corporation, located in
Cleveland, Ohio, to manufacture and supply 400 functional
electrical stimulators (FES) and ancillary items during 1998.
Biocontrol is currently completing shipment on a
previous order for 200 stimulators.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits-Press Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper, CEO
DATED: December 3, 1997
BICO
BIOCONTROL TECHNOLOGY, INC.
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Release: Immediate
For More Information, Call:
Investors Media
Diane McQuaide
Susan Taylor
1.412.429.0673 phone
1.412.279.9455 phone
1.412.279.9690 fax
1.412.279.9447 fax
BIOCONTROL TECHNOLOGY RECEIVES $2.146 MILLION CONTRACT
Pittsburgh, PA December 3, 1997 - Biocontrol Technology,
Inc. (Nasdaq:BICO) announced today that a new $2.146 million
contract has been received from NeuroControl Corporation, located
in Cleveland, Ohio, to manufacture and supply 400 functional
electrical stimulators (FES) and ancillary items during 1998.
Biocontrol is currently completing shipment on a previous
order for 200 stimulators.
The implantable FES is part of NeuroControl's Freehand
System which received Food and Drug Administration (FDA) market
clearance in August 1997. The Freehand uses electrical
stimulation to afford many quadriplegic patients increased
control over daily activities. According to NeuroControl,
more than 125,000 people with paralysis from the chest down due
to spinal cord injury may benefit from the Freehand System.
Worldwide, their conservative estimate is that there are over
500,000 people with spinal cord injury and approximately 25,000
new injuries per year.
Biocontrol has been manufacturing the functional electrical
stimulator since 1990 when it began working on the FES research
with Case Western Reserve University where the technology was
pioneered. When NeuroControl assumed commercialization of the
FES technology in 1995, Biocontrol was retained as the
manufacturer.
Biocontrol Technology, Inc. (www.bico.com) has its corporate
offices in Pittsburgh, PA and is involved in the development and
manufacture of biomedical devices and environmental products.
